Linkoping, Sweden

Rozalyn Simon

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Celluminova Ab. Active years: 2015.


% Patents Active = 100.0


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rozalyn Simon: Innovator in Neural Stem Cell Research

Introduction

Rozalyn Simon is a prominent inventor based in Linkoping, Sweden. She has made significant contributions to the field of molecular probes, particularly in the context of neural stem cells and neural cancer stem cells. Her innovative work has the potential to advance the understanding and detection of these critical cell types.

Latest Patents

Rozalyn Simon holds 1 patent for her invention titled "Oligothiophene derivate as molecular probes." This invention relates to oligothiophene derivatives that bind specifically to neural stem cells and neural cancer stem cells. The methods developed in this patent allow for the detection of these cells in biological samples, providing valuable tools for research and potential therapeutic applications.

Career Highlights

Rozalyn is associated with Celluminova AB, where she continues to work on innovative solutions in the field of biotechnology. Her research focuses on the intersection of molecular biology and cancer research, aiming to improve diagnostic and therapeutic strategies.

Collaborations

Rozalyn collaborates with notable colleagues, including Ola Hermansson and Peter Konradsson. These partnerships enhance her research efforts and contribute to the advancement of knowledge in her field.

Conclusion

Rozalyn Simon's work exemplifies the impact of innovative research on understanding neural stem cells and cancer. Her contributions through patents and collaborations highlight her role as a key figure in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…